| |
| |
|
| Insider
Information: |
Peterson Amy C. |
| Relationship: |
EVP Prod Dev & Med Aff... |
| City: |
Camana Bay, Grand Cayman |
| State: |
E9 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
575,123 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$37,516,175 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
575,123 |
|
|
| Total
Value |
$37,516,175 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Beigene Ltd |
BGNE |
CMO, Immuno-oncology |
2018-12-18 |
194,569 |
2016-08-22 |
0 |
Premium* |
|
|
Cytomx Therapeutics, Inc. |
CTMX |
|
2023-03-16 |
58,433 |
2020-11-30 |
0 |
Premium* |
|
|
Exelixis Inc |
EXEL |
EVP Prod Dev & Med Aff... |
2024-02-23 |
322,121 |
2023-08-24 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
23 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| EXEL |
Exelixis Inc |
EVP Prod Dev & Med Aff & CMO |
• – – |
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
82,121 |
322,121 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP Prod Dev & Med Aff & CMO |
• – – |
2023-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
240,000 |
240,000 |
0 |
- |
|
| CTMX |
Cytomx Therapeutics, Inc. |
EVP, Chief Development Officer |
• • – |
2023-03-16 |
4 |
S |
$1.98 |
$8,425 |
D/D |
(4,257) |
58,433 |
0 |
- |
|
| CTMX |
Cytomx Therapeutics, Inc. |
EVP, Chief Development Officer |
• – – |
2022-07-20 |
4 |
S |
$1.42 |
$10,612 |
D/D |
(7,463) |
62,690 |
0 |
- |
|
| CTMX |
Cytomx Therapeutics, Inc. |
EVP, Chief Development Officer |
• – – |
2022-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
70,153 |
0 |
- |
|
| CTMX |
Cytomx Therapeutics, Inc. |
EVP, Chief Development Officer |
• – – |
2022-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
46,421 |
0 |
- |
|
| CTMX |
Cytomx Therapeutics, Inc. |
EVP, Chief Development Officer |
• – – |
2021-05-31 |
4 |
A |
$6.09 |
$20,206 |
D/D |
3,320 |
6,421 |
0 |
- |
|
| CTMX |
Cytomx Therapeutics, Inc. |
EVP, Chief Development Officer |
• – – |
2020-11-30 |
4 |
A |
$6.39 |
$19,822 |
D/D |
3,101 |
3,101 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2018-12-18 |
4 |
AS |
$131.74 |
$1,356,312 |
D/D |
(10,141) |
0 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2018-12-18 |
4 |
OE |
$29.10 |
$295,103 |
D/D |
10,141 |
10,141 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2018-12-17 |
4 |
AS |
$130.37 |
$1,317,224 |
D/D |
(9,859) |
0 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2018-12-17 |
4 |
OE |
$29.10 |
$286,897 |
D/D |
9,859 |
9,859 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2018-11-12 |
4 |
AS |
$111.10 |
$1,360,349 |
D/D |
(12,067) |
0 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2018-11-12 |
4 |
OE |
$29.10 |
$351,150 |
D/D |
12,067 |
12,067 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2018-11-09 |
4 |
AS |
$118.64 |
$1,593,163 |
D/D |
(13,222) |
0 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2018-11-09 |
4 |
OE |
$29.10 |
$384,760 |
D/D |
13,222 |
13,222 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2018-11-08 |
4 |
OE |
$29.10 |
$428,090 |
D/D |
14,711 |
14,711 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2018-11-08 |
4 |
AS |
$122.86 |
$1,854,577 |
D/D |
(14,711) |
0 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2018-08-23 |
4 |
AS |
$167.54 |
$975,666 |
D/D |
(5,769) |
0 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2018-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
44,564 |
269,566 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2017-11-13 |
4 |
AS |
$82.79 |
$298,747 |
D/D |
(3,601) |
0 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2017-08-22 |
4 |
D |
$5.39 |
$151,830 |
D/D |
(28,185) |
271,815 |
0 |
- |
|
| BGNE |
Beigene Ltd |
CMO, Immuno-oncology |
• – – |
2016-08-22 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
0 |
- |
|
23 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
